🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Denmark / NCT05060783
Recruiting Observational

Renal Cancer Detection With Liquid Biopsy

NCT05060783 · tracked via the Priya Life Science Denmark tracker
Phase
Observational
Started
2021-07-01
Last updated
2024-01-30

Condition(s) studied

Renal CancerOncocytoma

Investigational drug(s) / intervention(s)

GaGnosticGaGnosticGaGnostic

GaGnostic: Plasma

GaGnostic: Serum

GaGnostic: Urine

Study summary

Glycosaminoglycans (GAGs) were significantly altered in localized as well advanced RCC compared to healthy samples. In addition, GAG scores correlated with progression-free survival and overall survival (OS) in a prospective cohort of patients with metastatic ccRCC and localized RCC. However, it is still unknown whether alterations in plasma and urine GAGs are exquisitely specific to RCC or are shared by other benign lesions in the kidney, such as angiomyolipomas, oncocytomas, or PEComa.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patients who underwent CT-scan with suspicion of renal tumor and the scans show no sign of renal cancer. 2. For patient with ccRCC or oncocytoma, they should have a histological verified tumor (Biopsy or surgical specimen) 3. Sign up information consent 4. Can perform protocol procedure Exclusion Criteria: 1. Non-clear cell Renal cell carcinoma 2. RCC with pure sarcomatoid differentiation, also called sarcoma of the kidney 3. Use of heparin for concurrent disease in need of blood dilution (e.g. ongoing deep vein thrombosis or lung emboli). Note: use of of heparin for thrombus prophylaxis in conjunction with primary surgery or postoperatively ≤4 weeks will be allowed.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Zealand University Hospital Roskilde Denmark Recruiting

More Zealand University Hospital trials in Denmark

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05060783 on ClinicalTrials.gov ↗ ← All trials in Denmark